`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owner.
`__________________
`
`Case IPR2019-00688
`U.S. Patent 9,468,747
`__________________
`
`PATENT OWNER’S OBJECTIONS TO EVIDENCE
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.64, Patent Owner Opiant Pharmaceuticals, Inc.
`
`submits the following objections to the exhibits filed by Nalox-1 Pharmaceuticals,
`
`Case IPR2019-00688
`U.S. Patent 9,468,747
`
`LLC on February 19, 2019.
`
`Patent Owner objects to Exhibit 1004 under Federal Rules of Evidence
`
`(“FRE”) 106, 401, 402, and 403 as incomplete.
`
`Patent Owner objects to Exhibit 1005 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`Patent Owner objects to Exhibit 1006 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`Patent Owner objects to Exhibit 1012 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`Patent Owner objects to Exhibit 1017 under FRE 401, 402, 403, and 901 as
`
`irrelevant and not authenticated.
`
`Patent Owner objects to Exhibit 1018 under FRE 401, 402, 403, 801, 802,
`
`805, and 901 as irrelevant and inadmissible hearsay and not authenticated.
`
`Patent Owner objects to Exhibit 1024 under FRE 106, 401, 402, and 403 as
`
`irrelevant and incomplete.
`
`Patent Owner objects to Exhibit 1025 under FRE 106, 401, 402, 403, and
`
`901 as irrelevant, incomplete, and not authenticated.
`
`2
`
`
`
`
`
`Patent Owner objects to Exhibit 1039 FRE 106, 401, 402, and 403 as
`
`Case IPR2019-00688
`U.S. Patent 9,468,747
`
`incomplete.
`
`Patent Owner objects to Exhibit 1043 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`Patent Owner objects to Exhibit 1044 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`Patent Owner objects to Exhibit 1045 under FRE 106, 401, 402, and 403 as
`
`irrelevant and incomplete.
`
`Patent Owner objects to Exhibit 1050 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`Patent Owner objects to Exhibit 1054 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`Patent Owner objects to Exhibit 1063 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`Patent Owner objects to Exhibit 1065 under FRE 106, 401, 402, and 403 as
`
`incomplete and an improper compilation of multiple documents.
`
`Patent Owner objects to Exhibit 1066 under FRE 106, 401, 402, and 403 as
`
`incomplete.
`
`
`
`
`
`3
`
`
`
`
`Date: September 23, 2019
`
`
`
`Case IPR2019-00688
`U.S. Patent 9,468,747
`
`
`
`Respectfully submitted,
`
`/Jessica Tyrus Mackay/
`Robert F. Green (Reg. No. 27,555)
`Jessica Tyrus Mackay (Reg. No. 64,742)
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`(313) 883-8000
`jmackay@greengriffith.com
`
`Counsel for Patent Owner
`Opiant Pharmaceuticals, Inc.
`
`4
`
`
`
`Case IPR2019-00688
`U.S. Patent 9,468,747
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true
`
`and correct copy of the foregoing was served on September 23, 2019, by delivering
`
`a copy via electronic mail on the following attorneys of record:
`
`Yelee Y. Kim
`Janine A. Carlan
`Richard Berman
`Bradford Frese
`Christopher Yaen
`ARENT FOX LLP
`1717 K Street NW
`Washington, DC 20036
`Yelee.Kim@arentfox.com
`Janine.Carlan@arentfox.com
`Richard.Berman@arentfox.com
`Bradford.Frese@arentfox.com
`Christopher.Yaen@arentfox.com
`
`/Jessica Tyrus Mackay/
`
`Jessica Tyrus Mackay (Reg. No. 64,742)
`
`
`
`
`
`
`
`
`
`
`
`5
`
`